This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEHA215E_L.jpg
The company’s products include several types of ultra-rapid, portable and antigen-based coronavirus tests that have brought in millions in sales since the beginning of the pandemic.
The company said its non-COVID related products grew 17% in the third quarter, at constant exchange rates, boosted by higher demand for tuberculosis testing, which brought in $79 million.
Chief Executive Thierry Bernard said the company was on track to achieve its 2021 sales target and would cross more than $2 billion in net sales.
Qiagen (NYSE:QGEN) said its annual revenue will grow 15% compared to the prior forecast of 12% growth. It forecast adjusted diluted earnings per share of $2.48, from prior guidance of $2.42.
Qiagen said third-quarter adjusted earnings per share rose to $0.58 on a currency-adjusted basis, beating the $0.54 expected on average by analysts.
